Relevant bibliographies by topics / Biomarkers of neurodegenerative disease / Books

Books on the topic 'Biomarkers of neurodegenerative disease'

To see the other types of publications on this topic, follow the link: Biomarkers of neurodegenerative disease.
Author: Grafiati
Published: 4 September 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 books for your research on the topic 'Biomarkers of neurodegenerative disease.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Peplow, Philip V., Bridget Martinez, and Thomas A. Gennarelli, eds. Neurodegenerative Diseases Biomarkers. New York, NY: Springer US, 2022. http://dx.doi.org/10.1007/978-1-0716-1712-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ingelsson, Martin, and Lars Lannfelt, eds. Immunotherapy and Biomarkers in Neurodegenerative Disorders. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-3560-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lovestone, Simon. Biomarkers in brain disease. Boston, Mass: Published by Blackwell Pub. on behalf of the New York Academy of Sciences, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

service), ScienceDirect (Online, ed. Biomarkers in kidney disease. London: Academic, 2010.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

de Lemos, James A., ed. Biomarkers in Heart Disease. Oxford, UK: Blackwell Publishing Ltd., 2008. http://dx.doi.org/10.1002/9781444300208.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Patel, Vinood B., and Victor R. Preedy, eds. Biomarkers in Bone Disease. Dordrecht: Springer Netherlands, 2017. http://dx.doi.org/10.1007/978-94-007-7693-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Patel, Vinood B., and Victor R. Preedy, eds. Biomarkers in Cardiovascular Disease. Dordrecht: Springer Netherlands, 2015. http://dx.doi.org/10.1007/978-94-007-7741-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Preedy, Victor R., ed. Biomarkers in Liver Disease. Dordrecht: Springer Netherlands, 2016. http://dx.doi.org/10.1007/978-94-007-7742-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Preedy, Victor R., ed. Biomarkers in Bone Disease. Dordrecht: Springer Netherlands, 2016. http://dx.doi.org/10.1007/978-94-007-7745-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Patel, Vinood B., ed. Biomarkers in Kidney Disease. Dordrecht: Springer Netherlands, 2015. http://dx.doi.org/10.1007/978-94-007-7743-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Avila, Jesus, Jose J. Lucas, and Felix Hernandez, eds. Animal Models for Neurodegenerative Disease. Cambridge: Royal Society of Chemistry, 2011. http://dx.doi.org/10.1039/9781849732758.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Saghir, Atif N. Free radicals in neurodegenerative disease. Birmingham: University of Birmingham, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
13

Perneczky, Robert, ed. Biomarkers for Preclinical Alzheimer’s Disease. New York, NY: Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4939-7674-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Menéndez González, Manuel. Atlas of Biomarkers for Alzheimer's Disease. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-07989-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Perneczky, Robert, ed. Biomarkers for Alzheimer’s Disease Drug Development. New York, NY: Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4939-7704-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Buduneli, Nurcan. Biomarkers in Periodontal Health and Disease. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-37317-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Singh, Sarika, and Neeraj Joshi, eds. Pathology, Prevention and Therapeutics of Neurodegenerative Disease. Singapore: Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-13-0944-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Zetterberg, Henrik, and Jonathan M. Schott. Fluid Biomarkers Indicative of Neurodegenerative Diseases. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190233563.003.0008.

Full text
Abstract:
A major unifying feature of neurodegenerative diseases (NDDs) is excessive neuronal loss. Depending on when and where this occurs, patients may express distinct neurological and psychiatric symptoms. Neurodegeneration is accompanied by protein aggregation, inflammation, and microglial activation that may be drivers of the disease or in some circumstances may be protective reactions to the neurodegenerative process. A key development over the past decade has been our ability to leverage these accompanying central nervous system changes to develop clinically impactful biomarkers of specific NDDs. This has been crucial in helping us develop an understanding the time line of progression of these diseases, in their early diagnosis and to help target patients appropriately in therapeutic clinical trials, This chapter gives an overview of both established and novel fluid biomarkers for neurodegeneration, protein accumulation, inflammation, and microglial activation across different neurodegenerative diseases. Common as well as disease-specific biomarker changes in cerebrospinal fluid and blood are emphasized.
APA, Harvard, Vancouver, ISO, and other styles
19

Biochemical Biomarkers and Neurodegenerative Diseases. MDPI, 2021. http://dx.doi.org/10.3390/books978-3-0365-1721-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Karikari, Thomas K., Nicholas James Ashton, Henrik Zetterberg, and Kaj Blennow, eds. Blood Biomarkers of Neurodegenerative Diseases. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-88976-284-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Qidwai, Tabish, ed. Neurodegenerative Diseases - Multifactorial Degenerative Processes, Biomarkers and Therapeutic Approaches (First Edition). BENTHAM SCIENCE PUBLISHERS, 2022. http://dx.doi.org/10.2174/97898150409131220101.

Full text
Abstract:
This reference is the definitive guide to common neurodegenerative diseases that affect humans. The book covers mechanisms of some of the most well-known neurodegenerative diseases, their biomarkers, neuropharmacology, and emerging treatment strategies. The book introduces the subject of neurodegeneration by outlining the biochemistry, pathophysiology and multifactorial neurological mechanisms (the role of genetics, environmental factors and mitochondrial damage, for example). Next, it explains some of the most studied diseases, namely, Parkinson's Disease, Alzheimer's Disease, Huntington’s Disease, and Multiple Sclerosis. Subsequent chapters delve into current knowledge about diagnostic and immunological biomarkers, followed by a summary of novel therapeutic strategies. Special attention has been given to the role of medicinal plants in attempting to treat neurodegenerative diseases, as well as the public health burden posed by these conditions. Key Features - give readers an overview of multifactorial disease mechanisms in neurodegeneration - covers some major neurodegenerative diseases in detail - covers diagnostic and immunological biomarkers - explores current therapeutic strategies and drug targets in common neurodegenerative diseases - offers a simple presentation with references for advanced readers The book is a suitable reference for all readers, including students, research scholars, and physicians who are interested in the mechanisms and treatment of neurodegenerative diseases.
APA, Harvard, Vancouver, ISO, and other styles
22

Cummings, Jeffrey L., and Jagan A. Pillai. Neurodegenerative Diseases. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190233563.003.0001.

Full text
Abstract:
Neurodegenerative diseases (NDDs) are growing in frequency and represent a major threat to public health. Advances in scientific progress have made it clear that NDDs share many underlying processes, including shared intracellular mechanisms such as protein misfolding and aggregation, cell-to-cell prion-like spread, growth factor signaling abnormalities, RNA and DNA disturbances, glial cell changes, and neuronal loss. Transmitter deficits are shared across many types of disorders. Means of studying NDDs with human iPS cells and transgenic models are similar. The progression of NDDs through asymptomatic, prodromal, and manifest stages is shared across disorders. Clinical features of NDDs, including cognitive impairment, disease progression, age-related effects, terminal stages, neuropsychiatric manifestations, and functional disorders and disability, have many common elements. Clinical trials, biomarkers, brain imaging, and regulatory aspects of NDD can share information across NDDs. Disease-modifying and transmitter-based therapeutic interventions, clinical trials, and regulatory approaches to treatments for NDDs are also similar.
APA, Harvard, Vancouver, ISO, and other styles
23

Galimberti, Daniela, and Elio Scarpini. Neurodegenerative Diseases: Clinical Aspects, Molecular Genetics and Biomarkers. Springer, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
24

Galimberti, Daniela, and Elio Scarpini. Neurodegenerative Diseases: Clinical Aspects, Molecular Genetics and Biomarkers. Springer, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
25

Galimberti, Daniela, and Elio Scarpini. Neurodegenerative Diseases: Clinical Aspects, Molecular Genetics and Biomarkers. Springer, 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
26

Jay, Taylor R., Shane M. Bemiller, Lee E. Neilson, Paul J. Cheng-Hathaway, and Bruce T. Lamb. Neuroinflammation and Neurodegenerative Diseases. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190233563.003.0004.

Full text
Abstract:
Neuroinflammation has long been associated with many neurodegenerative diseases (NDDs). Immune-related genetic and environmental risk factors have recently been identified for NDDs, suggesting that neuroinflammation can play an active role in modifying NDD pathologies. Immune cells that underlie this neuroinflammatory response can have both beneficial and detrimental roles in NDDs. These cells can engage in clearance of debris and provide important survival factors to neighboring neurons. However, these cells can also release inflammatory molecules that promote oxidative stress and excitotoxic damage in surrounding neurons, and aberrantly clear healthy cells and structures from the brain. In turn, the cells within the brain play important roles in determining the phenotype and function of these immune cells, and changes in the interaction among these cells in the context of disease can lead to detrimental immune cell activation. There has been recent interest in developing inflammation-related biomarkers to help diagnose NDDs and immune-targeted therapeutics.
APA, Harvard, Vancouver, ISO, and other styles
27

Cummings, Jeffrey L., and Kate Zhong. Clinical Trials and Drug Development in Neurodegenerative Diseases. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190233563.003.0018.

Full text
Abstract:
This chapter describes the common therapeutic targets, approaches to clinical trial design, biomarkers, and therapeutic interventions across neurodegenerative disorders (NDDs). Each unique NDD-Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), etc.-has a unique phenotype associated with the regional cell population most affected. Each disease, however, is associated with protein misfolding, oxidation, inflammation, apoptosis, and cell death. If vulnerable cell populations include transmitter source nuclei, transmitter deficits also emerge (e.g. cholinergic abnormalities in AD and dopaminergic deficits in PD). Biomarkers show regionally appropriate brain atrophy or process-related cerebrospinal deficits. Clinical trial designs share features for symptomatic interventions (e.g. cholinesterase inhibitors in AD and dopamine agents in PD) and disease-modifying therapies. Biomarkers play similar roles in trials for NDD, including demonstrating target engagement and supporting disease modification. No disease-modifying therapies have been approved for any NDDs; all programs face similar pharmacokinetic, pharmacodynamic, and regulatory challenges in therapeutic development.
APA, Harvard, Vancouver, ISO, and other styles
28

Ellenstein, Aviva, Christina Prather, and Mikhail Kogan. Neurodegenerative Diseases: Parkinson’s and Alzheimer’s Diseases. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190466268.003.0020.

Full text
Abstract:
Neurodegenerative diseases increase in prevalence with aging. This chapter begins with a discussion of Parkinson’s disease. Optimally individualized treatment includes dopaminergic medications, physiotherapy, and multidisciplinary care. Evidence for integrative approaches is limited. Advances in genetics and biomarkers hold promise for subtype-specific, precision treatment in the near future. The second part of this chapter focuses on Alzheimer’s disease. Standard evaluation includes assessment for possible contributing factors that may worsen cognition, and management includes optimizing factors that may improve cognitive function. No disease-modifying medical approaches yet exist, but increasing emphasis on interventions to limit chronic inflammation and optimize brain metabolism remain fundamental in the integrative approach to Alzheimer’s disease. The new metabolic approach first described by Dr. Dale Bredesen is summarized and the importance of multidisciplinary care, with emphasis on early transition to palliative care when appropriate, is reviewed.
APA, Harvard, Vancouver, ISO, and other styles
29

Bekris, Lynn M., and James B. Leverenz. Genetics of Neurodegenerative Diseases. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190233563.003.0010.

Full text
Abstract:
A great deal has been discovered about Neurodegenerative disorders (NDDs) including Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, dementia with Lewy bodies . This includes genetic variants associated with both sporadic and autosomal dominant NDDs. These findings have been crucial in our understanding the underlying factors that drive neuropathological changes and in clarifying the time line of biomarker changes in presymptomatic autosomal dominant mutation carriers. While much is still to be learned, these findings will play an important role in the future of neurodegenerative prediction, diagnosis, and treatment. This chapter summarizes the current genetic knowledge related to both the sporadic and autosomal dominant forms of neurodegenerative disease.
APA, Harvard, Vancouver, ISO, and other styles
30

Borowsky, Beth, and Cristina Sampaio. Experimental Therapeutics. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199929146.003.0017.

Full text
Abstract:
Bringing safe and effective treatments to patients with Huntington’s disease (HD) will require evaluation in properly designed and conducted clinical trials. Such clinical trials will require appropriate tools and practices, including therapeutics, patient registries, biomarkers, endpoints, trial design, and analysis tools. This chapter provides insight into the advances being made in each of these areas and highlights the challenges remaining. Lessons learned from prior HD trials as well as from trials in other neurodegenerative diseases affect our view of future HD clinical development. With much interest from both pharmaceutical companies and academic researchers, this final chapter of the book actually opens a new chapter in the history of HD drug development.
APA, Harvard, Vancouver, ISO, and other styles
31

van der Burg, Jorien M. M., N. Ahmad Aziz, and Maria Björkqvist. Peripheral Pathology. Oxford University Press, 2014. http://dx.doi.org/10.1093/med/9780199929146.003.0014.

Full text
Abstract:
Clinicians and researchers have previously focused on the neurologic and psychiatric aspects of Huntington’s disease (HD). However, it is becoming evident that many neurodegenerative disorders are also complicated by pathology in tissues outside the brain. Although many clinical features of HD can be ascribed to neuronal loss and dysfunction, there is accumulating evidence indicating a role for the pathology of non-neuronal tissues in the disease process. Mutant huntingtin is expressed throughout the body and may induce pathology in parallel in both the brain and other organs. Insights into peripheral pathology in HD have the potential of improving knowledge of key pathogenic mechanisms. This chapter describes peripheral manifestations of HD, including weight loss, muscle wasting, and cardiac dysfunction, and discusses how these might constitute targets for drug treatment as well as offering disease modeling systems and potential sources of biomarkers.
APA, Harvard, Vancouver, ISO, and other styles
32

Hu, Chaur-Jong, and Jean-Noël Octave, eds. Risk Factors and Outcome Predicating Biomarker of Neurodegenerative Diseases. Frontiers Media SA, 2019. http://dx.doi.org/10.3389/978-2-88945-802-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Woldstad, Christopher, Michael Boska, and Howard E. Gendelman. Neurological Complications of HIV in The Central Nervous System. Edited by Mary Ann Cohen, Jack M. Gorman, Jeffrey M. Jacobson, Paul Volberding, and Scott Letendre. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199392742.003.0026.

Full text
Abstract:
This chapter serves to highlight both the research advances made in understanding the effects of HIV on the nervous system and what lies ahead. Particular focus is given to both the effects HIV can play on the nervous system at the molecular and cellular levels and the comorbid conditions that affect neural function. Attention is also given to specific biomarkers to be used for increasing the effectiveness and availability of therapies. The pathogenesis of HIV-associated neurocognitive disorders (HAND) is comparable to that of several other neurodegenerative disorders, and their mechanistic similarities are also discussed in detail. With the introduction of antiretroviral therapy the life expectancy of persons with HIV has increased, with a concomitant decrease in the incidence of severe dementia. There has been a remarkable improvement in cognitive function with almost a complete reversal of associated symptoms of disease. Past and present disease manifestations and the implications for treatment are outlined in the chapter.
APA, Harvard, Vancouver, ISO, and other styles
34

Immunotherapy and Biomarkers in Neurodegenerative Disorders. Humana, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
35

Clinical use of biomarkers for neurodegenerative disorders. Frontiers SA Media, 2014. http://dx.doi.org/10.3389/978-2-88919-400-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Trull, Andrew K., Lawrence M. Demers, David W. Holt, Atholl Johnston, J. Michael Tredger, and Christopher P. Price, eds. Biomarkers of Disease. Cambridge University Press, 2002. http://dx.doi.org/10.1017/cbo9780511545962.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

W, Langston J., and Young Anne B. 1947-, eds. Neurotoxins and neurodegenerative disease. New York, N.Y: New York Academy of Sciences, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
38

Trojanowski, J. O. PENN Neurodegenerative Disease Research. S Karger Pub, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
39

Crish, Samuel D., Robert W. Burgess, Denise M. Inman, Christine M. Dengler-Crish, Jason R. Richardson, and Brett Schofield, eds. Axonopathy in Neurodegenerative Disease. Frontiers Media SA, 2019. http://dx.doi.org/10.3389/978-2-88945-680-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Prasad, Kedar N. Neurodegenerative Disease and Micronutrients. CRC Press, 2014. http://dx.doi.org/10.1201/b17497.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Metal Related Neurodegenerative Disease. Elsevier, 2013. http://dx.doi.org/10.1016/c2012-0-03090-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Tröster, Alexander I., ed. Memory in Neurodegenerative Disease. Cambridge University Press, 1998. http://dx.doi.org/10.1017/cbo9780511544378.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

Metabolomics in Neurodegenerative Disease. MDPI, 2020. http://dx.doi.org/10.3390/books978-3-03928-041-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Metal Related Neurodegenerative Disease. Elsevier Science & Technology Books, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
45

Preedy, Victor R., and Vinood B. Patel. Biomarkers in Cardiovascular Disease. Springer, 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
46

Lemos, James de. Biomarkers in Heart Disease. Wiley & Sons, Incorporated, John, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
47

Biomarkers in Cardiovascular Disease. Elsevier - Health Sciences Division, 2018.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
48

Biomarkers in renal disease. New York: Nova Biomedical Books/Nova Science Publishers, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
49

Khan, Tapan. Biomarkers in Alzheimer's Disease. Elsevier Science & Technology Books, 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
50

Preedy, Victor R., and Vinood B. Patel. Biomarkers in Kidney Disease. Springer, 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Biomarkers of neurodegenerative disease' for other source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography